Literature DB >> 2147909

Doxazosin in combination with atenolol in essential hypertension: a double-blind placebo-controlled multicentre trial.

M Searle1, R Dathan, S Dean, C C Christensen, A Westheim.   

Abstract

Doxazosin (mean dose 11 mg) given once daily in combination with 100 mg atenolol (n = 44) was compared with placebo and atenolol (n = 43) in a double-blind, multicenter study in patients with mild to moderate essential hypertension. In the atenolol/doxazosin-treated group, standing blood pressure significantly decreased by 17.0/12.3 mm Hg compared to 6.2/6.7 mm Hg in the atenolol/placebo group whereas supine blood pressure decreased by 13.2/9.8 mm Hg and 9.2/6.0 mm Hg, respectively in the two groups. Serum lipids did not change significantly in either group. The majority of side-effects reported were mild and transient. This study confirms that doxazosin may be safely combined with a beta-blocker. Doxazosin proved to be well tolerated and effective in patients with blood pressure refractory to atenolol alone.

Entities:  

Mesh:

Substances:

Year:  1990        PMID: 2147909     DOI: 10.1007/bf00315116

Source DB:  PubMed          Journal:  Eur J Clin Pharmacol        ISSN: 0031-6970            Impact factor:   2.953


  6 in total

Review 1.  The effects of antihypertensive agents on serum lipids and lipoproteins.

Authors:  C K Lardinois; S L Neuman
Journal:  Arch Intern Med       Date:  1988-06

2.  Lipoproteins, cardiovascular disease, and death. The Framingham study.

Authors:  T Gordon; W B Kannel; W P Castelli; T R Dawber
Journal:  Arch Intern Med       Date:  1981-08

3.  Serum lipid changes in a one-year, multicenter, double-blind comparison of doxazosin and atenolol for mild to moderate essential hypertension.

Authors:  M H Frick; D A Cox; P Himanen; M Huttunen; T Pitkäjärvi; P Pörsti; L Pöyhönen; M L Pyykönen; P Reinikainen; P Salmela
Journal:  Am J Cardiol       Date:  1987-05-29       Impact factor: 2.778

4.  Postjunctional selectivity of alpha-blockade with prazosin, trimazosin, and UK-33,274 in man.

Authors:  W Singleton; C A Saxton; J Hernandez; B N Prichard
Journal:  J Cardiovasc Pharmacol       Date:  1982       Impact factor: 3.105

5.  The alpha 1-adrenoceptor antagonist profile of doxazosin: preclinical pharmacology.

Authors:  V A Alabaster; M J Davey
Journal:  Br J Clin Pharmacol       Date:  1986       Impact factor: 4.335

6.  Doxazosin in patients with hypertension.

Authors:  K A Conrad; T C Fagan; M J Mackie; P V Mayshar; S Lee; J F Souhrada; F C Falkner; J D Lazar
Journal:  Eur J Clin Pharmacol       Date:  1988       Impact factor: 2.953

  6 in total
  7 in total

Review 1.  beta-blockers. Drug interactions of clinical significance.

Authors:  I Blaufarb; T M Pfeifer; W H Frishman
Journal:  Drug Saf       Date:  1995-12       Impact factor: 5.606

Review 2.  Neurogenic hypertension: pathophysiology, diagnosis and management.

Authors:  Samuel J Mann
Journal:  Clin Auton Res       Date:  2018-07-04       Impact factor: 4.435

Review 3.  Doxazosin. An update of its clinical pharmacology and therapeutic applications in hypertension and benign prostatic hyperplasia.

Authors:  B Fulton; A J Wagstaff; E M Sorkin
Journal:  Drugs       Date:  1995-02       Impact factor: 9.546

4.  A simplified mechanistic algorithm for treating resistant hypertension: efficacy in a retrospective study.

Authors:  Samuel J Mann; Neal S Parikh
Journal:  J Clin Hypertens (Greenwich)       Date:  2012-03-12       Impact factor: 3.738

Review 5.  Drug therapy for resistant hypertension: simplifying the approach.

Authors:  Samuel J Mann
Journal:  J Clin Hypertens (Greenwich)       Date:  2010-11-08       Impact factor: 3.738

6.  Combined alpha/beta-blockade: an underused approach to the treatment of resistant hypertension.

Authors:  Samuel J Mann
Journal:  J Clin Hypertens (Greenwich)       Date:  2007-09       Impact factor: 3.738

7.  Psychosomatic research in hypertension: the lack of impact of decades of research and new directions to consider.

Authors:  Samuel J Mann
Journal:  J Clin Hypertens (Greenwich)       Date:  2012-07-26       Impact factor: 3.738

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.